These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 16609043)
1. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Sarkaria JN; Carlson BL; Schroeder MA; Grogan P; Brown PD; Giannini C; Ballman KV; Kitange GJ; Guha A; Pandita A; James CD Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2264-71. PubMed ID: 16609043 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Martens T; Laabs Y; Günther HS; Kemming D; Zhu Z; Witte L; Hagel C; Westphal M; Lamszus K Clin Cancer Res; 2008 Sep; 14(17):5447-58. PubMed ID: 18765536 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839 [TBL] [Abstract][Full Text] [Related]
4. Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration. Schulte A; Günther HS; Martens T; Zapf S; Riethdorf S; Wülfing C; Stoupiec M; Westphal M; Lamszus K Clin Cancer Res; 2012 Apr; 18(7):1901-13. PubMed ID: 22316604 [TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
6. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932 [TBL] [Abstract][Full Text] [Related]
8. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647. Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237 [TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Luwor RB; Johns TG; Murone C; Huang HJ; Cavenee WK; Ritter G; Old LJ; Burgess AW; Scott AM Cancer Res; 2001 Jul; 61(14):5355-61. PubMed ID: 11454674 [TBL] [Abstract][Full Text] [Related]
11. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. Quan AL; Barnett GH; Lee SY; Vogelbaum MA; Toms SA; Staugaitis SM; Prayson RA; Peereboom DM; Stevens GH; Cohen BH; Suh JH Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):695-703. PubMed ID: 15936158 [TBL] [Abstract][Full Text] [Related]
14. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
15. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Pandita A; Aldape KD; Zadeh G; Guha A; James CD Genes Chromosomes Cancer; 2004 Jan; 39(1):29-36. PubMed ID: 14603439 [TBL] [Abstract][Full Text] [Related]
16. Tumor growth inhibition with cetuximab and chemotherapy in non-small cell lung cancer xenografts expressing wild-type and mutated epidermal growth factor receptor. Steiner P; Joynes C; Bassi R; Wang S; Tonra JR; Hadari YR; Hicklin DJ Clin Cancer Res; 2007 Mar; 13(5):1540-51. PubMed ID: 17332300 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592 [TBL] [Abstract][Full Text] [Related]
18. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
19. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342 [TBL] [Abstract][Full Text] [Related]
20. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Bertotti A; Migliardi G; Galimi F; Sassi F; Torti D; Isella C; Corà D; Di Nicolantonio F; Buscarino M; Petti C; Ribero D; Russolillo N; Muratore A; Massucco P; Pisacane A; Molinaro L; Valtorta E; Sartore-Bianchi A; Risio M; Capussotti L; Gambacorta M; Siena S; Medico E; Sapino A; Marsoni S; Comoglio PM; Bardelli A; Trusolino L Cancer Discov; 2011 Nov; 1(6):508-23. PubMed ID: 22586653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]